- NEWS FEATURE
- Update 01 September 2020
What the immune response to the coronavirus says about the prospects for a vaccine
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 585, 20-21 (2020)
doi: https://doi.org/10.1038/d41586-020-02400-7
Updates & Corrections
-
Update 01 September 2020: This story has been updated to reflect an extra report of SARS-CoV-2 reinfection, on 23 August.
References
Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. Epidemiol. Infect. 105, 435–446 (1990).
Kumar, R., Qureshi, H., Deshpande, S. & Bhattacharya, J. Ther. Adv. Vaccines Immunother. 6, 61–68 (2018).
Wu, F. et al. Preprint at medRxiv https://doi.org/10.1101/2020.03.30.20047365 (2020).
Long, Q.-X. et al. Nature Med. 26, 1200–1204 (2020).
Seow, J. et al. Preprint at medRxiv https://doi.org/10.1101/2020.07.09.20148429 (2020).
Rodda, L. B. et al. Preprint at medRxiv https://doi.org/10.1101/2020.08.11.20171843 (2020).
Le Bert, N. et al. Nature https://doi.org/10.1038/s41586-020-2550-z (2020).
Sette, A. & Crotty, S. Nature Rev. Immunol. 20, 457–458 (2020).
Mateus, J. et al. Science https://doi.org/10.1126/science.abd3871 (2020).